Form 4: Cidara Therapeutics Director Bonnie L. Bassler Acquires Stock Options
SEC Form 4 Filing
Director Bonnie L. Bassler acquired stock options in Cidara Therapeutics, Inc. on July 18, 2024.
Summary
- On July 18, 2024, Bonnie L. Bassler, a director of Cidara Therapeutics, Inc., acquired 2,125 stock options.
- The exercise price of these options is $12.64.
- The options vest on the earlier of the first anniversary of the grant date or the day prior to the Issuer's 2025 annual meeting of stockholders.
- The options expire on July 17, 2034.
- Following the transaction, Bassler directly owns 2,125 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of stock option grants to a director, neither particularly positive nor negative.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. It's a routine part of corporate governance and regulatory compliance.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders.
Key Dates
| Date | Description |
|---|---|
| 07/18/2024 | Date of transaction: Bonnie L. Bassler acquired stock options. |
| 07/17/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.